GlassScriptPhysician profile
Deepinder Dhaliwal
NPI 1588637094
$64,960.26
in general payments reported to CMS, 2019-2025
24 companies · $4,436 in 2025
The $4,436 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $9,790 · 2021: $11K · 2022: $1,565 · 2023: $3,134 · 2024: $22K · 2025: $4,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Food and Beverage: $3,184 · Travel and Lodging: $1,510 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,445.00 |
| Food and Beverage | $3,184.35 |
| Travel and Lodging | $1,509.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $365.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $11,826.71 | 2019-2025 | Star S4 Ir, Catalys System, Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $10,090.90 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $9,708.97 | 2022-2025 | Teneo, Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $9,376.96 | 2019-2022 | |
| Ocular Therapeutix, INC. | $5,210.75 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $4,969.38 | 2024-2025 | Xdemvy |
| Merck Sharp & Dohme LLC | $3,209.00 | 2019-2025 | |
| Shire North American Group INC | $3,000.00 | 2019 | |
| Horizon Therapeutics Plc | $2,500.00 | 2020 | |
| Allergan, INC. | $1,498.24 | 2019-2020 | |
| Oyster Point Pharma, INC. | $855.22 | 2022 | |
| Lensar, INC. | $714.78 | 2023 | Lensar Laser System |
| Dompe US, INC. | $648.51 | 2020-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $543.28 | 2019-2024 | Cequa |
| Abbvie INC. | $370.15 | 2023-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $132.29 | 2019 | |
| Eyepoint US, INC. | $107.78 | 2019 | |
| Amgen INC. | $89.55 | 2024 | Tepezza |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Glaukos Corporation | $43.08 | 2021-2025 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepinder Dhaliwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.